Download presentation
Presentation is loading. Please wait.
Published byΙόλη Βλαστός Modified over 6 years ago
1
Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update
2
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
3
Defining DMD
4
Prevalence and Burden of DMD
5
DMD Inheritance
6
DMD Mutations
7
DMD Reading Frame Disruption
8
Early Signs and Symptoms of DMD
9
Progression of DMD
10
Tests to Confirm the Diagnosis of DMD
11
Coordinated Care Model for DMD
12
Proactive Rather Than Reactive Respiratory Care for DMD
13
2016 AAN Guidelines for Corticosteroid Treatment of DMD
14
2016 AAN Guidelines for Corticosteroid Treatment of DMD (cont)
15
2016 AAN Guidelines for Corticosteroid Treatment of DMD (cont)
16
Corticosteroids Underused in Clinical Practice
17
Disease-Modifying Antisense Oligonucleotide
18
Three-Part Evidence-Based Guidelines for DMD Diagnosis and Treatment
19
Three-Part Evidence-Based Guidelines for DMD Diagnosis and Treatment (cont)
20
Conclusions
21
Abbreviations
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.